These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Mantle cell lymphoma: state of the art. Skarbnik AP; Goy AH Clin Adv Hematol Oncol; 2015 Jan; 13(1):44-55. PubMed ID: 25679973 [TBL] [Abstract][Full Text] [Related]
25. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077 [TBL] [Abstract][Full Text] [Related]
28. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
29. Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma. Rajendran J; Gopal A; Durack L; Fisher D; Press O; Eary J Cancer Biother Radiopharm; 2004 Dec; 19(6):738-45. PubMed ID: 15665621 [TBL] [Abstract][Full Text] [Related]
30. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma. Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683 [No Abstract] [Full Text] [Related]
31. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now? Atilla E; Atilla PA; Demirer T Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456 [TBL] [Abstract][Full Text] [Related]
33. Current treatment strategy and new agents in mantle cell lymphoma. Ogura M Int J Hematol; 2010 Jul; 92(1):25-32. PubMed ID: 20532841 [TBL] [Abstract][Full Text] [Related]
34. [Current therapeutic strategies for mantle cell lymphoma]. Dreyling M; Schnaiter A; Schmidt C; Hoster E Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of mantle cell lymphoma. Hitz F; Bargetzi M; Cogliatti S; Lohri A; Taverna C; Renner C; Mey U Swiss Med Wkly; 2013; 143():w13868. PubMed ID: 24226630 [TBL] [Abstract][Full Text] [Related]
36. Current overview and treatment of mantle cell lymphoma. Schieber M; Gordon LI; Karmali R F1000Res; 2018; 7():. PubMed ID: 30109020 [TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphoma: advances in biology and therapy. Smith MR Curr Opin Hematol; 2008 Jul; 15(4):415-21. PubMed ID: 18536582 [TBL] [Abstract][Full Text] [Related]
38. Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved? Dreyling M; Hiddemann W Curr Opin Oncol; 2008 Sep; 20(5):487-94. PubMed ID: 19106649 [TBL] [Abstract][Full Text] [Related]
39. [Treatment for mantle cell lymphoma]. Izutsu K Rinsho Ketsueki; 2017; 58(10):2026-2032. PubMed ID: 28978845 [TBL] [Abstract][Full Text] [Related]
40. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. Nazeef M; Kahl BS Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]